Trade name: CONTROL IMMUNODIAGNOSTICO VITROS * FOR HBsAg. ANVISA registry number: 10132590637. Risk class: IV. Product code 6800598. Lots affected and imported in Brazil: 0860, 0870, 0880, 0890, 0908. Lot lot affected: 352 units. 의 안전성 경고

Agência Nacional de Vigilância Sanitária (ANVISA)에 따르면, 해당 안전성 경고 는 Brazil 에서 JOHNSON & JOHNSON DO BRASIL IND. E COM. DE PROD. PARA SAÚDE LTDA; Ortho Clinical Diagnostics 에 의해 제조된 제품과 관련되어 있습니다.

이것은 무엇인가요?

안전성 경고는 의료기기 제품과 관련된 중요한 정보와 권고사항을 담고 있습니다. 물론 안전성 경고가 배포되었다고 해서 해당 제품이 무조건 안전하지 않은 제품이라는 것은 아닙니다. 보건의료업계 종사자와 의료기기 사용자들에게 배포되는 안전성 경고에는 회수(recall)도 포함될 수 있습니다. 제조사가 안전성 경고를 작성하기도 하지만, 보건당국에서 작성하는 경우도 있습니다.

데이터에 대해 더 자세히 알아보기 여기
  • 사례 유형
    Safety alert
  • 사례 ID
    2025
  • 날짜
    2016-11-25
  • 사례 국가
  • 사례 출처
    ANVISA
  • 사례 출처 URL
  • 비고 / 경고
    Brazilian data is current through June 2018. All of the data comes from Anvisa, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of data from the U.S. and Brazil.
  • 데이터 추가 비고
    According to company information: This is a situation in which the use of the product is not likely to cause adverse health consequences. Action required of laboratories that have the affected lot: • Discontinue use and discard the remaining inventory of affected batches of VITROS HBsAg Controls. (NOTE: Until you receive your replacement order, store the open-reconstituted bottles in the frozen form for up to 4 weeks.) • Forward this notification if you have provided the affected lot (s) outside your laboratory. • Place this notification next to each VITROS System that processes the VITROS Controls for HBsAg • Fill out and return the Receipt Confirmation form. If there is no alternative batch of VITROS HBsAg Controls in your inventory, it is acceptable to continue to use the affected lot (s) by following these instructions: • Control results must be within acceptable limits on the day of reconstitution (Day 1). • Store the open-reconstituted vials in the frozen form for up to 4 weeks. We recommend measuring the aliquot of the open-reconstituted material before freezing, so that several aliquots of the same vial can be used. If you wish to notify technical complaints and adverse events use the following channels: Notivisa: Notices of adverse events (AE) and technical complaints (QT) for products subject to Sanitary Surveillance should be made through the NOTIVISA System. To access the System, you must register and select the Health Professional option, if you are a liberal professional or the Institution / Entity option, if you are a professional of an institution / entity. Technovigilance System: Patient or citizen can notify through the Technovigilance System / SISTEC access through the link
  • 원인
    The company noticed through its global customer complaints system that signal / cutoff (s / c) results increased when negative controls were used. the investigation confirmed that the results generated with the use of these negative control lots showed a deviation in the mean results (s / c) as the product approached its 5-day open-reconstituted limit. the increased results (s / c) may also be observed with the positive control.
  • 조치
    Field Action No. 16000108, triggered under the responsibility of Johnson & Johnson. Field Action Hazard Rating: III Field Action Rating: Field Correction This field action identified internally by the company by the 16000108 encoding results are signal / cutoff (s / c) results increased when used the negative controls. The investigation confirmed that the results generated with the use of these negative control lots showed a deviation in the mean results (s / c) as the product approached its 5-day open-reconstituted limit. The increased results (s / c) may also be observed with the positive control.